8-K
filed February 11, 2025, 6:59 PM ET
CIK 0001267813
M&A
confidence high
sentiment neutral
materiality 0.85
MARINUS PHARMACEUTICALS, INC.: M&A transaction — Marinus acquired by Immedica for $0.55/share; merger completed, stock to be delisted
MARINUS PHARMACEUTICALS, INC.
- Tender offer closed Feb 6 with ~67.4% of shares tendered; merger effective Feb 11, 2025.
- Aggregate consideration ~$32.3M; shareholders receive $0.55 cash per share.
- Marinus common stock to cease trading on Nasdaq; company becomes Immedica subsidiary.
- All directors and officers replaced; Anders Edvell named CEO, Simon Falk Treasurer, Nina Fleck Secretary.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Scott Braunstein departed as Director at MARINUS PHARMACEUTICALS, INC..
- Action
- ceased to be a director
- Role
- Director
Exact text from the filing
each of Scott Braunstein, Tim Mayleben, Elan Ezickson, Seth Fischer, Marvin Johnson, and Christine Silverstein ceased to be a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Christina Shafer departed as Chief Commercial Officer at MARINUS PHARMACEUTICALS, INC..
- Action
- ceased to be an officer
- Role
- Chief Commercial Officer
Exact text from the filing
Christina Shafer (Chief Commercial Officer) ... ceased to be officers of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Christine Silverstein departed as Director at MARINUS PHARMACEUTICALS, INC..
- Action
- ceased to be a director
- Role
- Director
Exact text from the filing
each of Scott Braunstein, Tim Mayleben, Elan Ezickson, Seth Fischer, Marvin Johnson, and Christine Silverstein ceased to be a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nina Fleck was appointed as Director at MARINUS PHARMACEUTICALS, INC..
- Action
- became director
- Role
- Director
Exact text from the filing
Simon Falk and Nina Fleck became the directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Scott Braunstein departed as President and Chief Executive Officer at MARINUS PHARMACEUTICALS, INC..
- Action
- ceased to be President and Chief Executive Officer
- Role
- President and Chief Executive Officer
Exact text from the filing
Mr. Braunstein ceased to be President and Chief Executive Officer of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Anders Edvell was appointed as President and Chief Executive Officer at MARINUS PHARMACEUTICALS, INC..
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
Anders Edvell was appointed President and Chief Executive Officer of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Simon Falk was appointed as Treasurer at MARINUS PHARMACEUTICALS, INC..
- Action
- appointed
- Role
- Treasurer
Exact text from the filing
Simon Falk was appointed Treasurer of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Simon Falk was appointed as Director at MARINUS PHARMACEUTICALS, INC..
- Action
- became director
- Role
- Director
Exact text from the filing
Simon Falk and Nina Fleck became the directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nina Fleck was appointed as Secretary at MARINUS PHARMACEUTICALS, INC..
- Action
- appointed
- Role
- Secretary
Exact text from the filing
Nina Fleck was appointed Secretary of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Marvin Johnson departed as Director at MARINUS PHARMACEUTICALS, INC..
- Action
- ceased to be a director
- Role
- Director
Exact text from the filing
each of Scott Braunstein, Tim Mayleben, Elan Ezickson, Seth Fischer, Marvin Johnson, and Christine Silverstein ceased to be a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tim Mayleben departed as Director at MARINUS PHARMACEUTICALS, INC..
- Action
- ceased to be a director
- Role
- Director
Exact text from the filing
each of Scott Braunstein, Tim Mayleben, Elan Ezickson, Seth Fischer, Marvin Johnson, and Christine Silverstein ceased to be a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Elan Ezickson departed as Director at MARINUS PHARMACEUTICALS, INC..
- Action
- ceased to be a director
- Role
- Director
Exact text from the filing
each of Scott Braunstein, Tim Mayleben, Elan Ezickson, Seth Fischer, Marvin Johnson, and Christine Silverstein ceased to be a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Seth Fischer departed as Director at MARINUS PHARMACEUTICALS, INC..
- Action
- ceased to be a director
- Role
- Director
Exact text from the filing
each of Scott Braunstein, Tim Mayleben, Elan Ezickson, Seth Fischer, Marvin Johnson, and Christine Silverstein ceased to be a director of the Company
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
MARINUS PHARMACEUTICALS, INC. underwent a change of control involving Immedica Pharma AB for $0.55 per share (closed 2025-02-11).
- Action
- change of control
- Counterparty
- Immedica Pharma AB
- Consideration
- $0.55 per share
- Closing
- 2025-02-11
Exact text from the filing
a cash tender offer to acquire all of the outstanding shares of common stock (the “ Company Common Stock ”), par value $0.001 per share, of the Company (the “ Shares ”), for $0.55 per share (such amount, as it may be adjusted in accordance with the Merger Agreement, the “ Offer Price ”), in cash, subject to any applicable withholding taxes and without
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.